|
| Press Releases |
|
 |
|
| Tuesday, December 1, 2020 |
|
|
BioVaxys Provides Viral Vaccine Platform Program Update |
| BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) ("BioVaxys" or "the Company") is pleased to announce that it has received further data from its successfully completed murine model study demonstrating that immunizing mice with two doses of BVX-0320, its COVID-19 vaccine candidate, induced high levels of antibodies against the S1 fragment of the SARS-CoV-2 spike protein associated with inhibition of the binding of the virus to cells of the respiratory tract. more info >> |
|
| Monday, November 30, 2020 |
|
|
BioVaxys Provides Viral Vaccine Platform Program Update |
| BioVaxys Technology Corp. (CSE: BIOV) is pleased to announce that it has received further data from its successfully completed murine model study demonstrating that immunizing mice with two doses of BVX-0320, its COVID-19 vaccine candidate, induced high levels of antibodies against the S1 fragment of the SARS-CoV-2 spike protein associated with inhibition of the binding of the virus to cells of the respiratory tract. more info >> |
|
| Wednesday, November 11, 2020 |
|
|
BioVaxys Announces 96.4 Percent Positive Antibody Immune Response Results from an In Vivo Murine Model Study of Its SARS-CoV-2 Vaccine |
| BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) ("BioVaxys") is pleased to announce that results from its preclinical animal study (also known as the "murine model study") of BVX-0320, its Covid-19 vaccine candidate, show that the vaccine elicits a positive immune response against the SARS-CoV-2 s-spike protein. more info >> |
|
| Monday, November 2, 2020 |
|
|
BioVaxys Files Patent Application for Novel COVID-19 Diagnostic for T-Cell Immunity |
| BioVaxys Technology Corp. (CSE: BIOV) ("BioVaxys" or "the Company"), a world leader in haptenized protein vaccine research and development, announced today that it has filed a Provisional Patent Application with the U.S. Patent and Trademark Office entitled METHOD AND KIT FOR DETECTION OF CELL MEDIATED IMMUNE RESPONSE related to the potential development of a diagnostic for evaluating the presence or absence of a T-cell immune response to SARS-CoV-2, the virus that causes COVID-19. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Hola Prime Plans to Enter Futures Trading to Solve One of Finance's Most Persistent Problems: Complexity
May 23, 2025 20:00: JST
|
|
|
Hola Prime Plans to Enter Futures Trading to Solve One of Finance's Most Persistent Problems: Complexity
May 23, 2025 19:00 HKT/SGT
|
|
|
sureWin Nominated for Best iGaming Platform 2025 in SiGMA Awards
May 23, 2025 19:00: JST
|
|
|
sureWin Nominated for Best iGaming Platform 2025 in SiGMA Awards
May 23, 2025 19:00 HKT/SGT
|
|
|
Fujitsu and Tokai National Higher Education and Research System utilize AI to accelerate clinical research and tackle 'drug loss' in Japan
May 23, 2025 17:29 JST
|
|
|
三菱商事、経営戦略2027の実現に向けた人事領域の取り組みについて発表
May 23, 2025 14:00: JST
|
|
|
Lockheed Martin and Fujitsu Strengthen Japan Industry Collaboration with SPY-7 Supplier Selection and Strategic Agreements
May 23, 2025 13:36 JST
|
|
|
NIED, Fujitsu, SDS and Mitsubishi Electric sign joint research agreement to advance Japan Disaster Charter operational framework
May 23, 2025 13:35 JST
|
|
|
Honda Expands Production Capacity by Adding New Production Line at Fourth Motorcycle Plant in India
May 23, 2025 12:17 JST
|
|
|
Honda Reaches 500 Million-Unit Milestone in Cumulative Global Motorcycle Production
May 23, 2025 11:32 JST
|
|
|
東海国立大学機構と富士通、生成AIを用いた診療データの活用により治験候補患者の選定に貢献
May 23, 2025 10:30: JST
|
|
|
Five Toyota Group Companies to Accelerate Skill Development and Innovation in AI and Software
May 23, 2025 10:51 JST
|
|
|
52TOYS即將赴港上市 打造IP玩具新標桿
May 23, 2025 07:59 HKT/SGT
|
|
|
52TOYS即将赴港上市 打造IP玩具新标杆
May 23, 2025 07:36 HKT/SGT
|
|
|
DCLI Drives Fleet Efficiencies with BlackBerry Radar Deployment Across 100,000 Chassis
May 22, 2025 19:56 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
